A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

NCT04515849 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of the drug cotadutide in adults who have both type 2 diabetes and chronic kidney disease.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 248 people

Who can join Ages 18–79 · all sexes

Timeline Started 2020-08 · est. completion 2022-03

Where 83 sites · Australia, Canada, Germany, Japan, New Zealand, Poland, Spain, United Kingdom

What this study is testing ClinicalTrials.gov NCT04515849 ↗

Description as written by the study sponsor.

A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.

Treatments tested

Cotadutide 100 micrograms also known as MEDI0382 Drug

Cotadutide 100 micrograms administered subcutaneously
Cotadutide 300 micrograms also known as MEDI0382 Drug

Cotadutide 300 micrograms administered subcutaneously
Cotadutide 600 micrograms also known as MEDI0382 Drug

Cotadutide 600 micrograms administered subcutaneously
Semaglutide also known as Ozempic Drug

Semaglutide 1.0 miligrams administered subcutaneously
Placebo Drug

Placebo administered subcutaneously

Main thing measured	The Primary Endpoint Was Percentage Change in UACR of Cotadutide at Different Dose Levels Compared to Placebo After 14 Weeks
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus, Chronic Kidney Diseases
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04515849 ↗